Sustained Therapeutics Advancing Clinical Trials for Novel Drug Delivery Platform

A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics is evaluating a sustained release platform technology that could revolutionize how we treat pain and significantly improve the lives of individuals living with chronic pain. Sustained Therapeutics’ patented medication is a designed to relieve both acute and chronic pain over longer periods with fewer side effects than the current standard of care. A successful Phase I clinical trial resulted in a reduction in pain scores for three quarters of participants, with the effects lasting up to four weeks from a single dose...READ MORE

Zymeworks Provides Corporate Update On Key Strategic Priorities And Outlook For 2023

Zymeworks Inc., a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year. Highlights include:

• updated key priorities and focus on enterprise value framework
• Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022
• Announces additional financial guidance on expected cash runway; provides unaudited cash and cash resources balance as of December 31, 2022
• Announces recommended Phase 2 dose (RP2D) for zanidatamab zovodotin (ZW49)...READ MORE

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Algernon Pharmaceuticals, a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance the Company’s psychedelic DMT stroke program. The Company has valued the psychedelic DMT research program at USD $20M and has formally completed an asset transfer and trademark license agreement, transferring all DMT research program assets into AGN Neuro...READ MORE

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

Aurinia Pharmaceuticals Inc. announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review directed at Aurinia’s U.S. Patent No. 10,286,036, as well as settlement of the ongoing patent infringement litigation in the United States related to Sun’s CEQUA® product...READ MORE

STEMCELL Technologies President and CEO Dr. Allen Eaves Appointed to the Order of Canada

STEMCELL Technologies announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honourable Mary Simon, the Governor General of Canada. One of the nation’s highest forms of recognition, the Order of Canada recognizes people who make extraordinary contributions to Canadian society...READ MORE

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-In and Advances Partnership for Zanidatamab

Jazz Pharmaceuticals plc and Zymeworks Inc. announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks’ zanidatamab in key markets, including the U.S., Europe and Japan, pursuant to the license and collaboration agreement entered into in October 2022...READ MORE

The Cervix Screening HPV Pilot Implementation Team Receives BC Cancer Excellence Award for Innovation and Discovery in Action

The BC Cancer Excellence Awards provide an opportunity to shine a light on the inspiring people and teams who help ensure that British Columbians receive world-class, patient-centred cancer screening, treatment and support, and benefit from new discoveries that are helping change the face of cancer...READ MORE

Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc

Bioasis Technologies Inc., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier and the treatment of central nervous system disorders in areas of high unmet medical need, announced the following amendments to the terms of the previously announcement arrangement agreement with Midatech Pharma plc...READ MORE

CASTL Launches 2023 Short Courses Training Calendar

The Canadian Alliance for Skills and Training in Life Sciences, a national initiative to address the future skills needs of the fast-growing biomanufacturing sector, has launched its 2023 Short Course Calendar. Delivered virtually and in-person at the new CASTL Biomanufacturing Training Facility in Charlottetown, Prince Edward Island, the instructor-led short courses cover all aspects of the biopharmaceutical manufacturing process...READ MORE

Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators, a novel platform of immunotherapies designed to restore innate immune function, is excited to announce a new collaboration with Associate Professor Jonas Fuxe and his research team at the Karolinska Institute in Stockholm, Sweden, to characterize the molecular targets of Qu’s SSI therapy at the tissue level that lead to resolution of disease...READ MORE

Pfizer and BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized COMIRNATY® Original & Omicron BA.4/BA.5 as a 10-μg booster dose for children 5 through <12 years of age. This booster is approved for use at least 6 months after completing the primary course of the companies’ original COVID-19 vaccine (COMIRNATY)...READ MORE

Apply to MedTech Innovator 2023

MedTech Innovator is the largest and highest performing accelerator of medical technology in the world and the medtech industry’s premiere showcase and competition for innovative medical device, digital health and diagnostic companies. The accelerator is remote-friendly, having operated as a virtual program since 2015. MedTech Innovator is a founder-friendly nonprofit and do not require equity or fees for participation. Companies that have raised up to a Series C are eligible to apply...READ MORE

Research, Innovation Make People’s Lives Better

A new, artificial intelligence-guided point-of-care ultrasound imaging platform is under development at the University of British Columbia (UBC) as one of 18 new research projects funded by the B.C. Knowledge Development Fund (BCKDF) to improve the lives of British Columbians. Through the BCKDF, the Government of B.C. is providing more than $4.3 million for projects at UBC’s Vancouver and Okanagan campuses, UVic, SFU and VIU in fields such as health, natural resources and technology...READ MORE

Manager, Analytical Sciences

Manager of Analytical Sciences is a key leader with cross-functional responsibilities in manufacturing, process development, formulation development, QA, regulatory and supply chain to plan, coordinate, and execute analytical development activities and quality control. Collaborate with process R&D, technology transfer teams, and troubleshooting method related issues and root cause analysis for analytical deviations and investigations. The candidate will also ensure that method development and validation timelines and budgets are met, and drive for operation excellence in data review, batch release testing, stability studies, and laboratory investigations.

LEARN MORE

Product Manager, Laboratory Operations

As the Product Manager on the Laboratory Operations team, you will play a key role in understanding the challenges that arise for people who work in laboratories that focus on genomic sequencing, research and diagnostics. Reporting to the Head of Product Management, you will be responsible for creating product roadmaps, identifying pain points and potential improvements to address with our software, and making challenging decisions about feature priority. Ultimately, your goal is to work with various stakeholders to determine whether the solutions we build make the cut, solve the problem, and further enable the work of the customers: molecular diagnostics laboratories. 

LEARN MORE

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies, driven by a singular mission—to make a difference for people impacted by cancer.

As an industry leader in antibody–drug conjugate(ADC) technology, Seagan pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of their four approved medicines are built on this technology.

Seagan also focuses their research efforts on novel targeted small molecule therapies building a portfolio of proprietary immuno-oncology agents.

Visit Website

VoxCell is creating an extraordinary line of solutions for the drug development industry and the field of Oncology research by creating vascularized cancer tissue models.

Voxcell's tissue models will increase confidence in new drug candidates, decrease the failure rate (currently more than 95% of drugs in the pipeline fail), and impact the speed for new therapies to get to market.

Visit Website